• Synaptic Reelin-SFK Pathway: Key to Ketamine’s Antidepressan

  2026-05-18

  This study demonstrates that intact Reelin signaling through Apoer2 and Src family kinases (SFKs) is essential for ketamine’s rapid antidepressant and synaptic effects. Disruption of this pathway impairs both behavioral and synaptic responses to ketamine, highlighting a critical permissive mechanism underlying treatment resistance.

• Okadaic acid (A4540): Practical Guidance for Phosphatase Inh

  2026-05-18

  Okadaic acid is a potent, marine-derived protein phosphatase 1 inhibitor widely used to dissect phosphorylation-dependent signaling and apoptosis mechanisms in cellular and biochemical assays. It is ideal for workflows requiring selective, nanomolar-level inhibition of PP1 and PP2A, but should not be used in systems where phosphatase specificity or solvent compatibility is uncertain. All quantitative guidance is grounded in product specifications and workflow best practices.

• Meropenem Trihydrate in Resistance Profiling and Infection R

  2026-05-17

  Meropenem trihydrate, a potent carbapenem antibiotic from APExBIO, enables advanced antimicrobial resistance and infection modeling workflows. Explore its role in metabolomics-driven diagnostics and how optimized protocols accelerate both basic and translational research against multidrug-resistant pathogens.

• Syringin Enhances Sunitinib Efficacy in Renal Cell Carcinoma

  2026-05-16

  This study identifies syringin—a natural compound from Acanthopanax senticosus—as a novel agent that not only suppresses renal cell carcinoma (RCC) cell proliferation but also potentiates the efficacy of sunitinib by targeting the EGFR/PI3K/Akt pathway. These findings provide a mechanistic foundation for overcoming sunitinib resistance in RCC and suggest new avenues for combinatorial therapy.

• Cisplatin (SKU A8321): Optimizing Cytotoxicity and Tumor Ass

  2026-05-15

  This article delivers scenario-driven, evidence-based guidance for biomedical researchers using Cisplatin (SKU A8321) in cell viability and tumor inhibition assays. It addresses real-world challenges in assay reproducibility, protocol design, and product selection, highlighting how APExBIO’s Cisplatin supports reliable, interpretable results across cancer research and chemoresistance studies.

• Efficient iPSC Differentiation into Retinal Ganglion Cells v

  2026-05-15

  This study introduces a reproducible, chemically defined protocol using dual SMAD and Wnt pathway inhibition to efficiently differentiate induced pluripotent stem cells (iPSCs) into highly pure retinal ganglion cells (RGCs). The findings enable robust in vitro modeling of glaucoma and support the development of regenerative strategies for optic neuropathies.

• Ciprofloxacin in Antimicrobial Resistance Modeling: Molecula

  2026-05-14

  Explore how Ciprofloxacin, a leading fluoroquinolone antibiotic, enables advanced modeling of antimicrobial resistance gene transmission and genomic dynamics. This article offers an in-depth molecular perspective distinct from standard usage guides.

• Amikacin Sulfate: Targeted Delivery & Intracellular Efficacy

  2026-05-14

  Amikacin Sulfate delivers potent, targeted antibacterial action, enabling precision therapy against non-tuberculous mycobacterial infections. This guide details advanced workflows, troubleshooting, and the translational edge conferred by intracellular dendritic cell delivery—facilitating high local efficacy with reduced systemic toxicity.

• Dissecting P. aeruginosa Resistance: ampC/ampD Mutations and

  2026-05-13

  This study elucidates how specific ampC and ampD mutations drive ceftolozane-tazobactam resistance and imipenem susceptibility shifts in Pseudomonas aeruginosa, using advanced semi-mechanistic PKPD modeling. The findings refine our understanding of adaptive versus acquired resistance and offer a framework for precisely characterizing complex resistance mechanisms in clinical isolates.

• Astrocyte-to-Motoneuron Reprogramming via Ascl1-Myt1l-Pou3f2

  2026-05-13

  The referenced study demonstrates that a four-factor transcriptional cocktail (Ascl1, Myt1l, Pou3f2, Isl1) can directly reprogram spinal astrocytes into motoneuron-like cells. This approach offers a promising alternative to stem cell therapies for spinal cord injury, advancing prospects for regenerative medicine.

• Elobixibat Hydrate: Optimizing IBAT Inhibitor Workflows in G

  2026-05-12

  Elobixibat hydrate empowers GI and metabolic research with selective IBAT inhibition, enabling reproducible modeling of chronic idiopathic constipation and metabolic modulation. This article details best-practice workflows, advanced applications, and troubleshooting strategies for maximizing data quality and translational insight.

• Plerixafor (AMD3100): Precision CXCR4 Inhibition for Transla

  2026-05-12

  Explore how Plerixafor (AMD3100) enables precise CXCR4 inhibition in cancer metastasis and hematopoietic stem cell mobilization research. This in-depth article delivers new insights for advanced assay design and translational strategies.

• Capsaicin (C6366): Data-Driven Solutions for Cell Assays

  2026-05-11

  This article addresses five real-world laboratory scenarios where reproducibility, assay design, and data interpretation are challenged in cell viability, proliferation, and cytotoxicity studies. It details how Capsaicin (SKU C6366) from APExBIO delivers reliable, quantitative solutions—backed by mechanistic and protocol evidence—across pain, inflammation, and cancer research models.

• A1 vs. Plerixafor: Advancing CXCR4 Inhibition in Colorectal

  2026-05-11

  Khorramdelazad et al. present A1, a novel fluorinated CXCR4 inhibitor, and demonstrate its superior anti-tumor efficacy over AMD3100 (Plerixafor) in preclinical colorectal cancer models. Their work highlights distinct molecular, cellular, and in vivo advantages of A1 and offers new directions for targeting the CXCL12/CXCR4 axis in cancer research.

• Zolmitriptan as a 5-HT1B Receptor Agonist: Advanced Workflow

  2026-05-10

  Unlock reproducible migraine research with Zolmitriptan—a selective 5-HT1B receptor agonist from APExBIO. This guide details practical protocol enhancements, solubility solutions, and troubleshooting tips, empowering researchers to achieve robust, high-fidelity results in serotonin receptor pharmacology.

15329 records 4/1022 page Previous Next 12345 下5页 Last page